Literature DB >> 9545339

Characterization of V3 loop-Pseudomonas exotoxin chimeras. Candidate vaccines for human immunodeficiency virus-1.

D J FitzGerald1, C M Fryling, M L McKee, J C Vennari, T Wrin, M E Cromwell, A L Daugherty, R J Mrsny.   

Abstract

To develop a candidate vaccine for human immunodeficiency virus, type 1 (HIV-1), chimeric proteins were constructed by inserting sequences derived from the V3 loop of gp120 into a nontoxic form of Pseudomonas exotoxin (PE). Inserts of 14 or 26 amino acids, constrained by a disulfide bond, were introduced between domains II and III of PE. V3 loop-toxin proteins expressed in Escherichia coli and corresponding to either MN (subtype B) or Thai (subtype E) strains, were recognized by strain-specific monoclonal anti-gp120 antibodies. When loop sequences were introduced into an enzymatically active form of the toxin, there was no loss of toxin-mediated cell killing, suggesting that these sequences were co-transported to the cytosol. Sera from rabbits injected with nontoxic PE-V3 loop chimeras were reactive for strain-specific gp120s in Western blots, immunocapture assays, enzyme-linked immunosorbent assays, and neutralized HIV-1 infectivity. Since toxin vectors were designed to receive oligonucleotide duplexes encoding any V3 loop sequence, this approach should allow for the production of V3 loop-toxin chimeras corresponding to multiple HIV isolates.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9545339     DOI: 10.1074/jbc.273.16.9951

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.486


  6 in total

1.  An optimally constrained V3 peptide is a better immunogen than its linear homolog or HIV-1 gp120.

Authors:  Adi Moseri; Subramanyam Tantry; Yael Sagi; Boris Arshava; Fred Naider; Jacob Anglister
Journal:  Virology       Date:  2010-03-26       Impact factor: 3.616

2.  Mimicking the structure of the V3 epitope bound to HIV-1 neutralizing antibodies.

Authors:  Amit Mor; Eugenia Segal; Brenda Mester; Boris Arshava; Osnat Rosen; Fa-Xiang Ding; Joseph Russo; Amnon Dafni; Fabian Schvartzman; Tali Scherf; Fred Naider; Jacob Anglister
Journal:  Biochemistry       Date:  2009-04-21       Impact factor: 3.162

3.  Dual-function vaccine for Pseudomonas aeruginosa: characterization of chimeric exotoxin A-pilin protein.

Authors:  R Hertle; R Mrsny; D J Fitzgerald
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.609

4.  Bacterial Toxin Fusion Proteins Elicit Mucosal Immunity against a Foot-and-Mouth Disease Virus Antigen When Administered Intranasally to Guinea Pigs.

Authors:  Sreerupa Challa; Steven M Szczepanek; Debra Rood; Roger W Barrette; Lawrence K Silbart
Journal:  Adv Virol       Date:  2011-09-22

5.  Pseudomonas exotoxin kills Drosophila S2 cells via apoptosis.

Authors:  Ashima K Sharma; David FitzGerald
Journal:  Toxicon       Date:  2010-07-24       Impact factor: 3.035

6.  Intranasal immunization strategy to impede pilin-mediated binding of Pseudomonas aeruginosa to airway epithelial cells.

Authors:  Jennifer C Hsieh; Doris M Tham; Weijun Feng; Fan Huang; Selamawit Embaie; Keyi Liu; Deborah Dean; Ralf Hertle; David J Fitzgerald; Randall J Mrsny
Journal:  Infect Immun       Date:  2005-11       Impact factor: 3.609

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.